Reuters logo
BRIEF-Arrowhead Pharmaceuticals focuses resources on subcutaneous and extra-hepatic RNAi Therapeutics
November 29, 2016 / 9:30 PM / 10 months ago

BRIEF-Arrowhead Pharmaceuticals focuses resources on subcutaneous and extra-hepatic RNAi Therapeutics

Nov 29 (Reuters) - Arrowhead Pharmaceuticals Inc

* Arrowhead Pharmaceuticals focuses resources on subcutaneous and extra-hepatic RNAi Therapeutics

* Arrowhead Pharmaceuticals -Redeployment of resources to support development of rnai therapeutics that utilize new proprietary subcutaneous and extra-hepatic delivery systems

* Arrowhead Pharmaceuticals Inc says will discontinue development of clinical stage drug candidates ARC-520, ARC-521, and ARC-AAT

* Says company is reducing its workforce by approximately 30 percent

* All patient recruitment for ARC-520, ARC-521, and ARC-AAT has been halted and dosing discontinued

* Arrowhead Pharmaceuticals - More streamlined structure should enable co to continue to develop its programs rapidly, is intended to extend its cash runway into 2019 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below